Azura Ophthalmics
Azura is a clinical-stage company developing a therapy that targets the root cause of meibomian gland dysfunction and also contact lens discomfort. They aim to improve the lives of millions of people affected by ocular surface diseases, for which there are no effective pharmaceutical treatments today.
Therapeutic Area:
Ocular
AU $108M
Funding: Series B
2014
Year Founded
Unmet need and Commercial Potential
Over 300 million people worldwide suffer from dry eye disease, often due to blockage of the meibomian glands that release lubricating fluid onto the eye surface.
Azura is developing a new therapeutic approach that unblocks the glands and alleviates symptoms to significantly improve patients’ quality of life.
300 milion
People suffer from dry eye disease globally.
40 million US adults wear contact lenses, with 50% reporting dry eye sympoms.
Investors
